ACST Stock – (NASDAQ: ACST) is actually providing an update on the use

ACST
-1.84%
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or maybe the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is actually providing an update on the use of the “at-the market” equity of its providing plan.

As earlier disclosed, Acasti entered into an amended and restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and H.C. Wainwright & Co., LLC (collectively, the “Agents”), to carry out an “at-the market” equity offering program under which Acasti may well issue as well as promote from time to time its common shares having an aggregate offering price of up to $75 million throughout the Agents (the “ATM Program”).

ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the last distributions reported on January 27, 2021, Acasti issued an aggregate of 20,159,229 typical shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 zillion. The ATM Shares were offered at prevailing market prices averaging US$1.0747 per share. No securities had been offered throughout the facilities of the TSXV or maybe, to the expertise of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S-3 (No. 333-239538) as made effective on July 7, 2020, and the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate gross proceeds raised was given to the Agents in connection with their services. As a direct result of the latest ATM sales, Acasti has a total of 200,119,659 common shares issued and great as of March 5, 2021.

The additional capital raised has strengthened Acasti’s balance sheet and can supply the Company with supplemental freedom in its continuous review process to explore and evaluate strategic alternatives.

Approximately Acasti – ACST Stock

Acasti is a biopharmaceutical innovator that has historically centered on the research, development and commercialization of prescribed drugs using OM3 fatty acids delivered both as totally free fatty acids as well as bound-to-phospholipid esters, created from krill oil. OM3 fatty acids have extensive clinical proof of efficacy and safety for lowering triglycerides in people with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being created for individuals with serious HTG.

Forward Looking Statements – ACST Stock

Statements of this press release that are not statements of current or historical fact constitute “forward-looking information” within the meaning of Canadian securities laws as well as “forward-looking statements” within the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward-looking claims involve known and unknown risks, uncertainties, along with other unknown variables that can result in the particular outcomes of Acasti to be materially different from historical outcomes and even from any later results expressed or even implied by such forward looking statements. In addition to statements which explicitly describe such risks as well as uncertainties, people are urged to consider statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or any other similar expressions to be forward-looking and uncertain. Readers are actually cautioned not to place undue reliance on these forward looking statements, which speak only as of the particular date of this particular press release. Forward-looking statements in this press release include, but aren’t confined to, info or statements concerning Acasti’s strategy, future operations as well as its review of strategic alternatives.

The forward-looking assertions found in this specific press release are expressly qualified in the entirety of theirs by this alerting declaration, the “Special Note Regarding Forward Looking Statements” area contained in Acasti’s latest annual report on Form 10-K and quarterly report on Form 10 Q, which are available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com and also on the investor section of Acasti’s website at www.acastipharma.com. Many forward-looking assertions in that press release are manufactured as of the particular date of this particular press release.

ACST Stock – Acasti doesn’t undertake to redesign any such forward looking statements whether as a result of new info, future events or even otherwise, except as needed by law. The forward looking claims contained herein are also subject generally to assumptions and risks and uncertainties that are actually described from time to time in Acasti’s public securities filings with the Securities and exchange Commission and The Canadian securities commissions, like Acasti’s latest annual report on Form 10 K and quarterly report on Form 10 Q under the caption “Risk Factors“.

 

ACST Stock – (NASDAQ: ACST) is actually giving an update on the usage